Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phio PharmaceuticalsPHIO +3.85%28 EV-to-EBIT is 0.40 as of Jul. 21, 2026, which is 41% below its 10-year median of 0.68. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 374 Biotechnology companies, Phio Pharmaceuticals ranks better than 84.49% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Phio Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $-2.86 Mil.
Phio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals EV-to-EBIT Related Terms
Phio Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Phio Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phio Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phio Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's EV-to-EBIT falls into.
Phio Pharmaceuticals's current Enterprise Value is $-4.60 Mil.
Phio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals (PHIO) has a EV-to-EBIT of 0.40 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Phio Pharmaceuticals and its competitors. This is 41% below median its historical median of 0.68. According to the industry distribution chart, Phio Pharmaceuticals ranks #58 out of 374 companies in the Biotechnology industry, placing it in the top 15.5%.
Is Phio Pharmaceuticals' EV-to-EBIT too high?
Phio Pharmaceuticals' current EV-to-EBIT of 0.40 is 41% below median its 10-year median of 0.68. The Biotechnology industry median EV-to-EBIT is 12.87. Phio Pharmaceuticals' value of 0.40 is 96.9% below this industry median. Based on the distribution chart, Phio Pharmaceuticals ranks #58 out of 374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' EV-to-EBIT compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #58 out of 374 companies for EV-to-EBIT. This places Phio Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.87. Phio Pharmaceuticals' value of 0.40 is 96.9% below this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 12.87, Phio Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.87, based on 374 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phio Pharmaceuticals's current EV-to-EBIT of 0.40 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Phio Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phio Pharmaceuticals's current EV-to-EBIT is 0.40, which is 41% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current EV-to-EBIT of 0.40. The current EV-to-EBIT is 0.40, which is 41% below median its 10-year median of 0.68 and 96.9% below the Biotechnology industry median of 12.87. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current EV-to-EBIT is 0.40 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score
Get the complete analysis for PHIO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHIO has been successfully added to your 
